1
HR+ HER2- Metastatic Breast Cancer: Yesterday. Today. Tomorrow. ESMO ASIA 2017 INDUSTRY SATELLITE SYMPOSIUM Sponsored by Pfizer Oncology 12:45–14:15 | Friday, 17 November 2017 Room 325, Level 3, Suntec Singapore Convention & Exhibition Centre, Singapore Complimentary lunch will be provided to symposium attendees. PROGRAM Time Topic 12:45 Symposium welcome and faculty introduction 12:50 A molecular footprint: Where were we yesterday and today for mBC patients 13:05 A clinical footprint: Integrating CDK4/6 inhibitors in practice today and the evolving landscape 13:45 Asian experience with CDK4/6 inhibitors: A case study reflection 14:05 Rapid response panel discussion 14:15 Concluding remarks and session close Interactive keypad voting will be conducted during this symposium. Professor Hwai Loong, Kong HL Kong Medical Oncology Centre, Singapore CHAIRPERSON The symposium will be chaired by Professor HL Kong from HL Kong Medical Oncology Centre, Singapore. We will also be joined by world-renowned international experts in breast cancer to discuss the evolving landscape of HR+ HER2- mBC. Further information is available from your local Pfizer representative.
